Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Corcept Therapeutics Incorporated (NASDAQ:CORT) has been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $77.6667.

Several brokerages recently issued reports on CORT. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday. HC Wainwright cut their target price on Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday. Zacks Research downgraded shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Finally, Wolfe Research upgraded shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday.

Insider Transactions at Corcept Therapeutics

In other news, Director G Leonard Baker, Jr. purchased 100,000 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were bought at an average price of $33.14 per share, for a total transaction of $3,314,000.00. Following the completion of the purchase, the director owned 1,146,631 shares of the company’s stock, valued at $37,999,351.34. This trade represents a 9.55% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $40.87, for a total value of $817,400.00. Following the sale, the insider directly owned 1,235 shares in the company, valued at approximately $50,474.45. This trade represents a 94.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 60,000 shares of company stock valued at $2,241,035 over the last three months. 20.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Corcept Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. grew its holdings in Corcept Therapeutics by 438.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 65,797 shares of the biotechnology company’s stock worth $2,290,000 after buying an additional 53,574 shares in the last quarter. Corient Private Wealth LLC raised its stake in Corcept Therapeutics by 9.3% during the 4th quarter. Corient Private Wealth LLC now owns 7,035 shares of the biotechnology company’s stock valued at $245,000 after acquiring an additional 600 shares in the last quarter. SHP Wealth Management acquired a new position in Corcept Therapeutics during the 4th quarter worth $72,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Corcept Therapeutics in the fourth quarter worth $8,757,000. Finally, Virtu Financial LLC bought a new position in shares of Corcept Therapeutics in the fourth quarter worth $456,000. 93.61% of the stock is owned by institutional investors.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel — the regulatory win is the primary commercial catalyst and triggered the recent multi‑day rally due to survival benefit data and earlier‑than‑expected decision. FDA Approves (BusinessWire)
• Positive Sentiment: Analyst/firm support: multiple firms raised or reiterated positive views (Truist to “strong‑buy”, Canaccord price target increase reported, HC Wainwright kept a Buy rating), which supports upside potential as the market prices in Lifyorli’s commercial opportunity. Analyst Coverage (Benzinga)
• Positive Sentiment: Insider confidence signal: market commentary highlighted a mid‑March purchase by a director (~100,000 shares) that likely helped amplify bullish positioning ahead of the approval. Insider Buy Analysis (QuiverQuant)
• Neutral Sentiment: Market structure/volatility: trading was temporarily halted (LULD pause) and the name has posted very large intraday moves as investors re‑price the company; expect elevated volume and short‑term volatility. Market Reaction Coverage (Reuters)
• Negative Sentiment: Multiple securities‑class‑action firms have filed/issued alerts alleging misstatements tied to prior FDA issues and patent litigation — several firms are seeking lead plaintiffs and note an April 21, 2026 deadline; these suits create tangible legal and financial overhang. Hagens Berman Alert (GlobeNewswire)
• Negative Sentiment: Recent insider selling: Corcept disclosed a sale by William Guyer (11,767 shares on Mar 20), which may be viewed negatively by some investors despite offsetting director purchases. Insider Sale SEC Filing

Corcept Therapeutics Price Performance

CORT opened at $38.53 on Friday. The firm has a market cap of $4.10 billion, a price-to-earnings ratio of 46.99 and a beta of 0.29. Corcept Therapeutics has a fifty-two week low of $28.66 and a fifty-two week high of $117.33. The company’s 50-day moving average price is $37.47 and its 200 day moving average price is $61.00. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). The company had revenue of $202.13 million during the quarter, compared to analyst estimates of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The business’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.26 earnings per share. As a group, sell-side analysts expect that Corcept Therapeutics will post 1.36 earnings per share for the current year.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.